

At page 13, please amend the paragraph beginning at line 25 as follows:

-- Certain preferred COX-2 inhibitors include celecoxib (SC-58635), 5-bromo-s-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl] thiophene (DUP-697), flosulide (CGP-28238), meloxicam, 6-methoxy-2 naphthylacetic acid (6-MNA), Vioxx (MK-966), nabumetone (prodrug for 6-MNA), nimesulide, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398), 1-fluoro-4-[2-[4-methylsulfonyl)phenyl]-1-cyclopenten-1-yl] benzene (SC-5766), 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole (SC-58215), N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide (T-614); or combinations thereof. --

### **IN THE CLAIMS**

Please **amend** the claims as follows:

30. (Amended) A pharmaceutical composition comprising an analgesic combination consisting essentially of 5-(4-fluorophenyl)-1-[4-methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.

31. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof would be sub-therapeutic if administered without the 5-(4-fluorophenyl)-1-[4-methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof.

32. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof; and 5-(4-fluorophenyl)-1-[4-methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof are administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation.

35. (Amended) The pharmaceutical composition according to claim 30, wherein the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof synergistically potentiates the effect of the oxycodone and/or at least one pharmaceutically acceptable salt thereof but the oxycodone and/or at least one pharmaceutically acceptable salt thereof does not synergistically potentiate the effect of the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof.

36. (Amended) The pharmaceutical composition according to claim 34, wherein the oral solid dosage form includes a sustained release carrier which causes the sustained release of the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof; the oxycodone and/or at least one pharmaceutically acceptable salt thereof; or both the oxycodone and/or at least one pharmaceutically acceptable salt thereof and the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof when the dosage form contacts gastrointestinal fluid.

37. (Amended) A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof such that the dosing interval of the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

38. (Amended) The method of claim 37, wherein the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof; and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered orally.

39. (Amended) The method of claim 37, wherein the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered in a single oral dosage form.

40. (Amended) The method of claim 37, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof would be sub-therapeutic if administered without the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof.

41. (Amended) The method of claim 37, wherein the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof is administered before, simultaneously with, or after administration of the oxycodone and/or at least one pharmaceutically acceptable salt thereof, such that the dosing interval of the 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

42. (Amended) A method of reducing the oxycodone and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain, comprising co-administering said oxycodone and/or at least one pharmaceutically acceptable salt thereof with 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said oxycodone and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said oxycodone and/or at least one pharmaceutically acceptable salts thereof.

43. (Amended) A method of reducing the amount of 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain comprising co-administering said 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof with an effective amount of oxycodone and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said 5-(4-fluorophenyl)-1-[4-methylsulfonyl]phenyl]-3-trifluoromethyl 1H-pyrazole and/or at least one pharmaceutically acceptable salt thereof.

44. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.

45. (Amended) The method of claim 37, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.